Altimmune, Inc. (ALT) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

59NeutralDD: Jun 10, 2026Analyst: 64

paidReference price

USD 2.61 (10/06/2026)

domainMkt cap

$500.69M

pie_chartShares

192M

candlestick_chart52W

$2.56-$7.73

trending_downShort interest

21.1%

MEDIUMNASDAQHealth Care57 employeesFounded 1997

Verdict: Favorable Risk/Reward — High asymmetry, binary catalysts

Late-clinical biotech trading at ~1.05x net cash after a -62% drawdown from 52W highs. EV implied for the entire pipeline is only ~$29M despite FDA Breakthrough Therapy Designation in MASH and Phase 3 PERFORMA starting H2 2026. Strong cash floor ($2.79/sh) anchors downside (~5% to floor); upside is binary on Phase 3 execution and RECLAIM Q3 2026 AUD readout. Asymmetry favorable; outcome distribution is bimodal.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-10

Altimmune, Inc. (ALT)

Biotechnology · NASDAQ · Gaithersburg, MD

"Asymmetric dislocation — cash floor + binary catalyst near term"

Net cash ~95% of mkt cap Pre-revenue, $80M+ burn Breakthrough Therapy MASH 21% short interest CEO insider buying

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV (pemvidutide pipeline) + Net Cash Floor

Fair value base case

USD 5.76

Range: USD 2.50-USD 13.0

Reference price: USD 2.61 (10/06/2026)

Base upside/downside: +121%

Methodology: Probability-weighted FV = 0.25×$14.5 + 0.50×$6.25 + 0.25×$2.50 = $7.40 vs additive rNPV = $5.76. Both methods agree on directionally bullish setup (+96% to +152% from $2.94). Implied multiple sanity check: $5.76 base FV implies ~1.97x cash, vs peer median 10x for Phase 3 stage MASH; multiple expansion to even 2.5-3x cash on Phase 3 enrollment milestone would imply $7-8 base case. Sensitivity: ±5% PoS moves base FV ±$1.10. ⚠️ Not investment advice.

Component	Assumption	USD/share
Net cash floor (pro forma Apr 30, 2026)	$535M cash & ST investments / 192M shares outstanding	+2.79
Pemvidutide MASH rNPV	$1.5B peak sales × 4.0x multiple × 15% PoS × 0.70 PV disc / 192M	+3.28
Pemvidutide AUD option value	$300M peak × 3.0x × 10% PoS × 0.65 disc / 192M (RECLAIM Q3 2026 catalyst)	+0.30
Warrant dilution adjustment	75M outstanding warrants @ $3.00 strike × 50% exercise prob × $1.20 dilution drag	−0.61
FV base case	Sum of components above	≈ $5.76

Bull

$11–$18

Probability: 25%

Phase 3 PERFORMA starts on time H2 2026 with strong KOL coverage. RECLAIM AUD data Q3 2026 reads out positive. M&A interest emerges (Novo precedent on Akero). GLP-1/MASH competitive concerns recede. PoS re-rated to 30%+.

Base

$5.00–$7.50

Probability: 50%

Phase 3 starts, no major operational issues, AUD data mixed-to-positive. Pipeline value re-rated to ~$3-4/share. Some warrant dilution (50% exercise). Stock drifts toward rNPV fair value over 12-18 months.

Bear

$2.00–$3.00

Probability: 25%

Phase 3 delays, AUD readout disappoints, GLP-1 competition tightens, additional dilution required. Stock anchors near cash/share floor (decaying with burn). Floor erodes to $2.00-2.50 over 18-24 months.

Methodology: Methodology: Probability-weighted FV = 0.25×$14.5 + 0.50×$6.25 + 0.25×$2.50 = $7.40 vs additive rNPV = $5.76. Both methods agree on directionally bullish setup (+96% to +152% from $2.94). Implied multiple sanity check: $5.76 base FV implies ~1.97x cash, vs peer median 10x for Phase 3 stage MASH; multiple expansion to even 2.5-3x cash on Phase 3 enrollment milestone would imply $7-8 base case. Sensitivity: ±5% PoS moves base FV ±$1.10. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ $535M cash war chest post April 2026 raise

$225M oversubscribed public offering closed April 24, 2026 (priced at $3.00) brings cash, equivalents and short-term investments to ~$535M as of April 30, 2026. Management guides cash runway through Phase 3 MASH 52-week data readout in 2029, fully de-risking the funding hurdle that drove the 2024-2025 selloff.

⚠️ Methodology note: ALT is a pre-revenue, late-clinical biotech. Standard EV/EBITDA or P/E multiples are not meaningful. Fair value uses risk-adjusted NPV (rNPV) for the pemvidutide pipeline + net cash anchor, with explicit probability of success (PoS) and discount rates. Asymmetric profile: hard floor from cash, optionality from binary trial outcomes. This is a [DISLOCATION] thesis selected for screening; the DD derives FV independently.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

21.1%

~26.4M shares shorted out of ~125M float (or 19.4% of float per alt source). Days to cover elevated. Interpretation: high short interest reflects bear thesis on dilution, GLP-1 competition and Phase 3 risk. Squeeze risk on positive catalyst.

🔴 Share dilution (1Y)

+85%

From ~88M shares (mid-2025) to ~192M shares (June 2026). Causes: $75M Jan 2026 registered direct offering + $225M April 2026 public offering (64.25M shares + 10.75M pre-funded warrants + 75M coverage warrants @ $3.00 strike).

🔴 Buyback

No buyback program. Cash earmarked for Phase 3 MASH (PERFORMA) trial, Phase 2 AUD, and ALD program. Capital deployment priority: clinical execution, not shareholder return.

Short Interest — context

ALT — 21.1%

21.1%

Insider activity (Form 4): CEO Jerry Durso (appointed Jan 1, 2026) executed a $47K open-market purchase of 15,000 shares at $3.14 on April 1, 2026 — modest size but directional positive signal post-transition. Four directors received 48,800 stock options each at $2.82 strike on May 1, 2026 (grants, not open-market buys). No insider selling >$500K detected. No class action, short-seller report, or SEC investigation identified in last 12 months.

$Financial analysis — FY2025 / Q1 2026

Cash & ST investments

$535M

As of Apr 30, 2026 (post raise)

Net loss FY2025

−$88.1M

−7% YoY (improvement)

Q1 2026 EPS

−$0.18

Burn pace ~$80-85M/yr

Cash runway

~3.5Y

Through 2029 Ph3 data readout

Item ($M)	FY2023	FY2024	FY2025	FY2026E	Guidance 2026
Revenue	~0.0	0.02	0.04	~0.0	Pre-revenue (clinical)
R&D expense	−65.2	−72.5	−68.4	−95 to −110	Phase 3 ramp
G&A	−18.4	−22.6	−19.7	−22 to −25	Stable
Net loss	−78.6	−95.0	−88.1	−110 to −130	Trial-driven
Cash & ST investments (EOP)	126	170	~210	~460-490	Post April raise
Shares outstanding (M)	73	78	88	~192	+85% diluted

FY2026 figures Q1 actual + skill-estimated FY full-year. R&D acceleration mirrors Phase 3 PERFORMA launch expected H2 2026. Loss widens but cash flush.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	0.01	0.01	0.01	0.01	0.0
R&D expense ($M)	−16.4	−17.8	−18.2	−16.0	−18.5
Net loss ($M)	−21.2	−22.4	−21.7	−22.8	−22.5
End-of-period cash ($M)	148	132	113	210	332

Financial position and sustainability

Cash runway to Ph3 readout

~3.5Y

Pipeline progress (Ph2b → Ph3)

55%

Net cash vs market cap coverage

95%

Phase 2b IMPACT data quality

Strong

account_tree

Business model — Late-clinical biotech focused on MASH / metabolic-hepatic diseases

Pemvidutide: dual GLP-1 / glucagon agonist for liver disease

Altimmune's lead asset pemvidutide is a once-weekly subcutaneous GLP-1 receptor / glucagon receptor dual agonist, targeting MASH (metabolic dysfunction-associated steatohepatitis), AUD (alcohol use disorder), and ALD (alcohol-associated liver disease). FDA Breakthrough Therapy Designation granted in MASH (Jan 2026) following IMPACT Phase 2b 48-week data showing significant MASH resolution, dose-dependent fibrosis improvements, and durable weight loss. Phase 3 PERFORMA expected H2 2026; topline 52-week data in 2029. Strategy: capital-efficient, focused single-asset bet on best-in-class liver/metabolic mechanism.

Pemvidutide — MASH ~$1.5B peak peak (5-7% of $30B+ MASH TAM) 🟢 Ph3 starting H2 2026 Breakthrough Therapy Designation granted. Phase 2b IMPACT showed significant MASH resolution, anti-fibrotic activity, ~16% weight loss. Phase 3 PERFORMA targeting moderate-advanced fibrosis (F2-F3). Competes with MDGL Rezdiffra (approved), VKTX VK2735, AKRO efruxifermin. Pemvidutide — AUD ~$300-500M peak (de novo market) 🟡 RECLAIM Ph2 Q3 2026 Phase 2 RECLAIM in alcohol use disorder; topline data expected Q3 2026. Positive readout = pipeline diversification + addressable market expansion. Negative = isolated MASH bet. Pemvidutide — ALD Early-stage option value 🟡 Pre-Ph2 planning Alcohol-associated liver disease program in preclinical/early development. Smaller market but synergistic mechanism. Option value only in fair value model.

gavel

Legal, regulatory and risk analysis

Phase 3 PERFORMA execution risk

Critical

PERFORMA pivotal trial in MASH must show stat-sig improvement in fibrosis without worsening NASH. Phase 2b suggests path to success but enrollment, dosing, and competitive landscape (Rezdiffra approved) are real hurdles. Failure = ~70% stock decline to cash floor.

GLP-1 / MASH competitive pressure

High

Novo Nordisk, Lilly (tirzepatide), Madrigal (Rezdiffra approved), Akero (now owned by Novo), Viking — all developing or commercializing competing assets. Pemvidutide must differentiate on tolerability, efficacy, dosing. Class-effect risk on TAM share.

Additional dilution / warrant exercise

Moderate

75M coverage warrants @ $3.00 strike from April 2026 offering. Exercise = +$225M cash but +75M shares (additional 39% dilution). Trial cost overruns could trigger another raise. Track outstanding warrants and cash burn quarterly.

CEO/management transition risk

Moderate

New CEO Jerome Durso took over Jan 1, 2026 (formerly Intercept Pharmaceuticals CEO). Recent $47K open-market purchase positive. Track delivery on Q4 2025 commitments and Phase 3 initiation timeline as execution proof points.

Single-asset concentration

High

Pemvidutide drives ~95% of equity value. No commercial-stage backup. Failure of pemvidutide MASH or pivotal safety signal = near-total equity impairment. Pipeline diversification limited to indication-stacking on same molecule.

Net cash floor (post April 2026 raise)

Positive

$535M cash & ST investments anchor ~95% of current market cap. Cash/share ≈ $2.79 vs current price $2.94. Downside cushion limits losses in non-binary scenarios. Runway extends through Phase 3 52-week readout in 2029.

FDA Breakthrough Therapy Designation

Positive

January 2026 Breakthrough Designation for pemvidutide in MASH. Provides FDA engagement priority, potential accelerated review path, and signal validation of Phase 2b data. Material de-risking of regulatory pathway.

M&A optionality (Novo/Akero precedent)

Positive

Novo's $5.2B acquisition of Akero (May 2026) sets a clear M&A comp for Phase 3 MASH biotech. ALT at $564M = 11% of Akero deal size despite similar mechanism class. Strategic takeout possible post-PERFORMA enrollment progress; not in base case but real upside optionality.

article

SWOT analysis

Strengths

+$535M cash war chest covers all R&D through 2029 Ph3 readout
+FDA Breakthrough Therapy Designation in MASH (Jan 2026)
+Phase 2b IMPACT 48-week data: stat-sig MASH resolution + fibrosis + 16% weight loss
+Dual mechanism (GLP-1 + glucagon) differentiated vs pure-GLP-1 competitors
+Net EV ≈ $29M implies negative pipeline value — extreme dislocation

Weaknesses

−Pre-revenue, $80M+ annual burn, no path to operating cash flow
−Single-asset concentration: pemvidutide ~95% of equity value
−85% share count dilution YoY (88M → 192M shares)
−New CEO (Jan 2026): no track record at ALT yet

Opportunities

→MASH TAM $30B+ globally with only one approved drug (Rezdiffra)
→Novo-Akero precedent: strategic M&A at premium valuations
→AUD/ALD indication-stacking expands pemvidutide addressable market
→Cash-rich balance sheet allows opportunistic Ph3 acceleration if competitor data emerges

Threats

!Novo, Lilly, Madrigal, Viking competing in same MASH/metabolic space
!GLP-1 class effects on dosing, GI tolerability, real-world adherence
!21% short interest implies entrenched bear narrative
!Macro: biotech sector multiples sensitive to risk-off cycles

article

Summary by assessment area

🟢 Financial position — LOW RISK

$535M cash post April raise
No debt, no covenant risk
Runway through 2029 Ph3 readout
Cash covers ~95% of market cap

🔴 Clinical/execution risk — HIGH

Phase 3 PERFORMA pivotal binary outcome
Single-asset concentration
GLP-1/MASH competition crowded
RECLAIM Q3 2026 AUD data could disappoint

🟡 Asymmetric setup — FAVORABLE

Downside ~5% to cash floor ($2.79)
Upside +96% to base FV; +300%+ bull
R/R ratio favorable but binary outcome
Position-sizing critical (Kelly < 5%)

2026-09-30 regulatory

RECLAIM Phase 2 AUD topline data

short-term Impact: High Direction: Binary

Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder. Positive readout adds material option value (+$0.50-1.00/sh); negative isolates the MASH bet.

2026-12-31 regulatory

Phase 3 PERFORMA MASH trial initiation

medium-term Impact: High Direction: Bullish

PERFORMA Phase 3 pivotal trial of pemvidutide in MASH expected to start H2 2026. First-patient-dosed = key validation event for re-rating from cash-floor multiple.

2026-08-12 earnings

Q2 2026 earnings & business update

short-term Impact: Medium Direction: Neutral

Q2 2026 earnings expected ~mid-August 2026. Focus: updated cash burn, Phase 3 PERFORMA trial site activation, RECLAIM enrollment status. Validation of capital allocation post April raise.

2026-09-08 strategic

Investor conferences (Goldman Sachs, Wells Fargo Healthcare)

short-term Impact: Medium Direction: Neutral

Fall 2026 healthcare conferences typically include 1x1 management meetings. New CEO Durso narrative refinement; potential strategic partnership signaling.

2026-12-31 ma

MASH M&A precedent watch (Novo/Lilly)

medium-term Impact: High Direction: Bullish

Novo's $5.2B Akero acquisition (May 2026) created clear M&A comp for Phase 3 MASH biotech. Lilly, Pfizer, Roche could follow. ALT at $564M = strategic target post Ph3 initiation milestone.

2027-04-24 capital_markets

Warrant exercise window monitoring

long-term Impact: Medium Direction: Bearish

75M coverage warrants from April 2026 raise are exercisable at $3.00 strike. Above-strike exercise = +$225M cash but +39% additional dilution. Headwind on per-share valuation if stock rallies above $3.

2026-11-13 product

AASLD The Liver Meeting 2026 — Phase 2b extended data

medium-term Impact: Medium Direction: Bullish

Annual AASLD meeting (mid-November) is key MASH-community forum. Expect updated pemvidutide IMPACT data presentations, KOL coverage, and competitive readouts (Rezdiffra real-world data, VKTX, AKRO). Material signaling event.

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole — Asimmetria positiva", "en": "Verdict: Favorable Risk/Reward — Asymmetric setup"}, "verdict_text": {"it": "Biotech late-clinical scambiato a ~1.05x cassa con downside floor ~5% e upside binario +96% base, +400% bull. Pipeline pemvidutide in MASH con Breakthrough Therapy Designation, Phase 3 in partenza H2 2026. Position size piccola, conviction alta.", "en": "Late-clinical biotech trading at ~1.05x net cash with ~5% downside to floor and binary +96% base / +400% bull upside. Pemvidutide MASH pipeline with FDA Breakthrough Therapy Designation, Phase 3 starting H2 2026. Small position size, high conviction asymmetric bet."}, "bull_points": [ {"it": "Cassa $535M = 95% del market cap, floor solido a $2.79/azione", "en": "Cash $535M = 95% of market cap, hard floor at $2.79/share"}, {"it": "FDA Breakthrough Designation MASH + Phase 3 PERFORMA in partenza", "en": "FDA Breakthrough Designation in MASH + Phase 3 PERFORMA starting H2 2026"}, {"it": "Precedente M&A Novo/Akero a $5.2B = comparable diretto per re-rating", "en": "Novo/Akero M&A precedent at $5.2B sets clear comp for re-rating"} ], "bear_points": [ {"it": "Single-asset risk: pemvidutide = 95% del valore equity", "en": "Single-asset risk: pemvidutide drives 95% of equity value"}, {"it": "Concorrenza GLP-1/MASH intensa (Novo, Lilly, Madrigal, Viking)", "en": "Intense GLP-1/MASH competition (Novo, Lilly, Madrigal, Viking)"}, {"it": "Diluzione 85% YoY + 75M warrant esercitabili a $3.00", "en": "85% dilution YoY + 75M warrants exercisable at $3.00"} ], "risks": [ {"it": "Phase 3 PERFORMA fallisce o ritarda → drawdown a floor cassa", "en": "Phase 3 PERFORMA fails or delays → drawdown to cash floor"}, {"it": "Short interest 21% riflette tesi bearish entrenched", "en": "21% short interest reflects entrenched bearish thesis"}, {"it": "Esecuzione nuova leadership (CEO Durso da Gen 2026) non ancora provata", "en": "New leadership execution (CEO Durso since Jan 2026) not yet proven"} ] }

Sources & Disclaimer

Sources: SEC filings (10-Q Q1 2026, 8-K Mar-Apr-May 2026, S-1 / 424B5 for April 2026 offering), GlobeNewsWire press releases, Seeking Alpha, Stocktitan, StockAnalysis.com, Yahoo Finance, Reuters, Benzinga, Meyka (insider trades), Bloomberg, Investor Relations Altimmune. Market data — last verified close 2026-06-09: ALT ~$2.94, market cap ~$564M, 52W: $2.56–$7.73, shares outstanding ~192M. Short interest: 21.1%. Cash & ST investments as of Apr 30, 2026: ~$535M. Analyst consensus target $17.67 (6 analysts, Strong Buy, last refresh May 2026). ⚠️ Not investment advice. This document is for informational purposes only and does not constitute financial or investment advice.